Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Armanni–Ebstein lesion (AEL) is characterized by the vacuolization of tubular epithelial cells in the outer stripe of the outer medulla due to abnormal cytoplasmic glycogen accumulation. It typically occurs in patients with poorly controlled diabetes and is associated with hyperglycemia and glycosuria. Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) lowers blood glucose levels by blocking glucose reabsorption in the S1–S2 segments of the proximal tubules, thereby increasing urinary glucose excretion. This study aimed to investigate the relationship between SGLT2i use and AEL occurrence, which to the best of our knowledge has not been previously studied.
This multicenter retrospective study included patients aged ≥ 18 years who underwent renal biopsy between January 2019 to May 2025. Patients who underwent renal transplantation or had tubulointerstitial nephritis were excluded from the study. Among the included patients, those who were administered SGLT2i at the time of biopsy and whose specimens contained medullary tissue were analyzed for the presence of AEL and associated clinical characteristics. Patients who were not administered SGLT2i during the same period were used as controls. Propensity score matching (1:2) was conducted using age, sex, eGFR, HbA1c, diabetes history, and histological confirmation of diabetic nephropathy. After propensity score matching, AEL presence rates and odds ratios were analyzed.
The cohort consisted of 42 patients administered SGLT2i, of whom 27 (64.3%) were male. The median values and IQR ranges for age, eGFR, and HbA1c were 59.5 years [46.0–69.8], 43.1 mL/min/1.73 m² [33.3–56.9], and 6.20% [5.70–6.68], respectively. AEL was observed in 34 patients (81.0%), including 12 without diabetes (35.3%). There were no significant differences between AEL-positive and AEL-negative patients in terms of sex, age, eGFR, urinary glucose levels, history of diabetes, or histological confirmation of diabetic nephropathy. AEL-positive patients had significantly shorter height (163.8 cm vs 174.5 cm, p = 0.034), lower body weight (66.0 kg vs 80.2 kg, p = 0.032), and higher HbA1c levels (6.30% vs 5.65%, p < 0.01) than AEL-negative ones. After propensity score matching, one patient was excluded, leaving 33 and 65 patients in the SGLT2i and control groups, respectively. AEL was more frequently reported with SGLT2i use (81.8% vs 4.6%, p < 0.001; OR 93.0, 95% CI 21.6–400.0).
SGLT2i use was associated with an increased presence of AEL, regardless of the diabetes status. Among SGLT2i users, AEL-positive patients had higher HbA1c levels and lower height and body weight than AEL-negative ones. These findings suggest that AEL may be more likely to occur in individuals with higher systemic drug and glucose levels, leading to greater glucose exposure in tubular segments downstream of S1–S2.
